The AZD1222 candidate being developed by the University of Oxford, in coordination with pharmaceutical firm AstraZeneca, was found to be "completely successful" in phase 3 of the clinical trials. The vaccine would be rolled out in the UK and most parts of Europe by September. The government has ordered a production of 100 million doses in the initial round.